
Nova Mentis (OTC: NMLSF) Receives Health Canada Approval for First-Of-Its-Kind Psilocybin Clinical Trial
The human study will evaluate the Company’s proprietary psilocybin drug (NM-1001) in the treatment of Fragile X Syndrome Vancouver, British Columbia–(Newsfile Corp. – December 22, 2022) – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) […]